Adrenergic-cholinergic interactions in left atria: interaction of carbachol with alpha- and beta-adrenoceptor

Insights

Muscarinic agonists like carbachol reduce heart muscle contractions in rabbit left atria. This anti-adrenergic effect appears independent of cyclic AMP and may involve calcium influx antagonism.

Area of Science:

  • Cardiology
  • Pharmacology
  • Physiology

Background:

  • Muscarinic agonists modulate cardiac function through various signaling pathways.
  • Understanding their interaction with adrenoceptors is crucial for cardiac drug development.
  • Previous studies in ventricular muscle suggest cAMP-independent mechanisms for anti-adrenergic effects.

Purpose of the Study:

  • To investigate the functional interaction of muscarinic agonists with cAMP-generating and cAMP-independent agonists in rabbit left atria.
  • To elucidate the signaling mechanisms underlying the anti-adrenergic effects of muscarinic receptor stimulation in atrial tissue.

Main Methods:

  • Isolated rabbit left atrial strips were used to measure negative inotropic responses.
  • Experiments involved carbachol in the presence of isoproterenol, phenylephrine with timolol, and elevated extracellular calcium.
  • Cyclic AMP (cAMP) and cyclic GMP (cGMP) levels were measured.

Main Results:

  • Carbachol induced dose-dependent negative inotropic responses, potentiated by isoproterenol or phenylephrine/timolol, but not by elevated extracellular calcium.
  • Phenylephrine did not significantly affect cAMP levels in the presence of timolol.
  • Carbachol attenuated isoproterenol-induced cAMP increases, with greater negative inotropy than cAMP reduction.

Conclusions:

  • The anti-adrenergic effects of muscarinic agonists in left atria differ from those in ventricular muscle.
  • These effects may involve antagonism of alpha- and beta-adrenoceptor-mediated calcium influx.
  • The precise mechanism remains to be fully elucidated but appears to be cAMP-independent.

Related Concept Videos

Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...